BRAF and melanoma: While the advent of targeted therapies (i.e., BRAF and MEK inhibitors) and immune checkpoint inhibitors (i.e., ipilimumab, pembrolizumab, nivolumab) significantly improved recurrence and survival outcomes for melanoma patients, metastatic melanoma and therapy resistance still represent major challenges for clinicians [1].